|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Future studies with long-term follow-up are required to determine if pediatric BRAF V600E positive CNS-JXG neoplasms are a distinct entity in the L-group histiocytosis category or represent an expanded pediatric spectrum of ECD.
|
31685033 |
2019 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Future studies with long-term follow-up are required to determine if pediatric BRAF V600E positive CNS-JXG neoplasms are a distinct entity in the L-group histiocytosis category or represent an expanded pediatric spectrum of ECD.
|
31685033 |
2019 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The discovery of BRAF(V600E) mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis.
|
26566875 |
2016 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The coexistence of LCH and ECD in the same biopsy and the BRAF (V600E) mutation status in both histologic types support the recent re-classification of the histiocytic disorder into LCH, ECD, and "mixed histiocytosis", which reflects tumorigenesis for all three from a common progenitor cell.
|
26466952 |
2016 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The discovery of BRAF(V600E) mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis.
|
26566875 |
2016 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The coexistence of LCH and ECD in the same biopsy and the BRAF (V600E) mutation status in both histologic types support the recent re-classification of the histiocytic disorder into LCH, ECD, and "mixed histiocytosis", which reflects tumorigenesis for all three from a common progenitor cell.
|
26466952 |
2016 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients).
|
25003820 |
2014 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients).
|
25003820 |
2014 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Treatment with vemurafenib should be investigated in patients with malignant BRAF(V600E) histiocytosis.
|
22879539 |
2012 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Treatment with vemurafenib should be investigated in patients with malignant BRAF(V600E) histiocytosis.
|
22879539 |
2012 |